07:34 AM EDT, 03/23/2026 (MT Newswires) -- Apogee Therapeutics ( APGE ) stock was up 18% pre-bell Monday after the company said that 52-week maintenance data from Part A of its phase two trial of zumilokibart in patients with moderate-to-severe atopic dermatitis demonstrated durable maintenance response and "deepening" response for lesional and itch endpoints.

Indivior (INDV) shares were 13% higher following a 3.9% loss in the previous session.

Synopsys ( SNPS ) stock was up 4.2% after media reports over the weekend that Elliott Investment Management has built a multibillion-dollar stake in the company.